New gel aims to stop chemo side effect that makes hands hurt

NCT ID NCT07457671

Not yet recruiting Prevention Sponsor: Tarian Pharma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a gel called TAR-0520 to see if it can prevent hand-foot syndrome, a painful skin reaction caused by the chemotherapy drug capecitabine. About 25 people with breast or colorectal cancer will apply the gel to their hands twice daily for 12 weeks. Their feet will not be treated and will serve as a comparison. The goal is to check if the gel is safe and reduces the severity of hand-foot syndrome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAR-0520 gel
What this could lead to: If it works, this could point toward a way to prevent painful hand-foot syndrome in cancer patients taking capecitabine, improving their quality of life.
What could go wrong: This is a small, early-phase study with only 25 people. It may not show clear benefit, and the gel could cause local skin reactions or not reduce symptoms enough to matter.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer colorectal cancer hand-foot syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAND AND FOOT SYNDROME

Contacts and locations

Locations

Instiut Paoli-Calmettes

Marseille, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.